Circadian rhythms and cardiovascular health

Portaluppi, Francesco; Tiseo, Ruana; Smolensky, Michael H.; Hermida, Ramón C.; Ayala, Diana E.; Fabbian, Fabio

doi:10.1016/j.smrv.2011.04.003

Cited by 252 publications

(176 citation statements)

References 268 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, blocking the renin-angiotensin-aldosterone system by bedtime treatment seems to be an efficient means of reducing the asleep BP mean and increasing the sleep-time relative BP decline towards the normal dipper pattern. Despite the multiple factors influencing the mostly predictable daily BP variation and sleep-BP level, including rest-activity associated changes in behaviour, day-night cycles of environmental phenomena, and innate circadian (~24 h) rhythms in neuroendocrine, endothelial and haemodynamic variables [1,43,44], the impact of hypertension treatment-time on asleep BP regulation might thus be clinically relevant not only for CVD risk reduction-as previously documented [20][21][22], but also for preventing new-onset diabetes [32].…”

Section: Discussionmentioning

confidence: 98%

“…Specific features of the daily BP pattern determined by ambulatory BP (ABP) monitoring (ABPM) have been explored as biomarkers or mediators of target tissue injury and triggers of and risk factors for cardiovascular disease (CVD) events [1]. Numerous ABPM studies consistently substantiate the incidence of end-organ injury, and fatal and non-fatal CVD events are significantly associated with blunted sleep-time relative BP decline (so-called non-dipper BP pattern), not only in Electronic supplementary material The online version of this article (doi:10.1007/s00125-015-3748-8) contains peer-reviewed but unedited supplementary material, which is available to authorised users.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sleep-time BP: prognostic marker of type 2 diabetes and therapeutic target for prevention

et al. 2015

Self Cite

View full text Add to dashboard Cite

Aims/hypothesis We investigated the prognostic value of clinic and ambulatory BP (ABP) to predict new-onset diabetes and whether risk reduction is related to the progressive decrease of clinic BP or awake or asleep ABP. Methods We prospectively evaluated 2,656 individuals without diabetes, 1,292 men and 1,364 women, 50.6±14.3 years of age, with baseline BP ranging from normotension to hypertension according to ABP criteria. At baseline and annually (more frequently if hypertension treatment was adjusted based on ABP) thereafter, ABP and physical activity (wrist actigraphy) were simultaneously monitored for 48 h to accurately derive the awake and asleep BP means. Results During a 5.9-year median follow-up, 190 participants developed type 2 diabetes. The asleep systolic ABP mean was the most significant predictor of new-onset diabetes in a Cox proportional-hazard model adjusted for age, waist circumference, glucose, chronic kidney disease (CKD) and hypertension treatment. Daytime clinic BP and awake or 48 h ABP mean had no predictive value when corrected by the asleep ABP mean. Analyses of BP changes during follow-up revealed a 30% reduction in the risk of new-onset diabetes per 1-SD decrease in asleep systolic ABP mean, independent of changes in clinic BP or awake or 48 h ABP means.Conclusions/interpretation Sleep-time BP is a highly significant independent prognostic marker for new-onset diabetes. Alteration in sleep-time BP regulation seems to precede, rather than follow, the development of new-onset diabetes. Most important, lowering asleep BP, a novel therapeutic target requiring ABP evaluation, could be a significant method for reducing new-onset diabetes risk.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Sleep-time BP: prognostic marker of type 2 diabetes and therapeutic target for prevention

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Observed differences in characteristics and outcomes between AHF patients presenting during daytime vs. nighttime hours suggest potential different pathophysiological mechanisms or differences in disease severity. [1][2][3] Other acute cardiovascular processes, leading to myocardial infarction, myocardial ischemia, and sudden cardiac death occur more frequently in the early morning hours: 4 Circadian rhythms may contribute to their respective disease mechanisms. 5 Attempts to better understand potential circadian interactions from acute heart failure (AHF) clinical trials have been limited by operational constraints: Patients are primarily enrolled during 'working' hours -Monday through Friday, 0800 to 1700.…”

Section: Introductionmentioning

confidence: 99%

Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial

Pang

Teerlink

Boer-Martins

et al. 2017

American Heart Journal

View full text Add to dashboard Cite

“…The influence of formulation factors on the responses y 1 , y 3 , y 5 and y 8 is presented as scaled and centered coefficients and as the response surface plot in Fig. 3.…”

Section: Design Of Experiments Analysis In Vitro Drug Releasementioning

confidence: 99%

“…Blood pressure is characterized by predictable changes over 24 hours in synchrony with the rest-activity cycle. The rate of blood pressure rise at the commencement of diurnal activity is a predictor of the risk of morning stroke and acute coronary syndrome, and it is also hypothesized to be a trigger for myocardial infarction at that time of the day (4,5). Metoprolol is a cardioselective beta-blocker used in the management of hypertension, angina pectoris cardiac arrhythmias, myocardial infarction and heart failure.…”

mentioning

confidence: 99%

Piecewise function parameters as responses of the design of experiment in the development of a pulsatile release chronopharmaceutical system

Vonica-Gligor¹,

Tomuță

Leucuţa

2016

Acta Pharmaceutica

View full text Add to dashboard Cite

The aim of this work was to develop a pulsatile release system with metoprolol for chronotherapeutical use by coating swellable mini-tablets with Eudragit RS. To study the influence of the formulation factors (amount of coating polymer, plasticizer percentage in film coating and swelling agent percentage in mini-tablets), a Box-Behnken design of experiment (DoE) was used. To evaluate the influence of the studied factors on the sigmoid shape of the dissolution profile, piecewise function parameters were used as the responses of DoE. The results show that higher concentrations of coating polymer and higher concentrations of plasticizer polymer led to a thicker and more elastic polymeric film, which led to a delay in drug release. Using the parameters of the piecewise function as DoE responses, an optimum formulation with a sigmoid shape dissolution profile and a 2.5-h lag time followed by rapid drug release were obtained.

show abstract

Circadian rhythms and cardiovascular health

Cited by 252 publications

References 268 publications

Sleep-time BP: prognostic marker of type 2 diabetes and therapeutic target for prevention

Sleep-time BP: prognostic marker of type 2 diabetes and therapeutic target for prevention

Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial

Piecewise function parameters as responses of the design of experiment in the development of a pulsatile release chronopharmaceutical system

Contact Info

Product

Resources

About